Hair Loss Treatments Online: What's FDA-Approved and What Isn't

Two things on an online hair-loss menu are FDA-approved for hair loss itself: oral finasteride 1 mg and topical minoxidil. Both labels are public, and both say exactly what the product is approved to do.

Oral finasteride 1 mg

The brand is Propecia; generics are sold too. The FDA-approved label (NDA 020788, “Revised: 07/2022”) gives the indication plainly: “PROPECIA is indicated for the treatment of male pattern hair loss (androgenetic alopecia) in MEN ONLY.” It adds two limits — “Efficacy in bitemporal recession has not been established” and “PROPECIA is not indicated for use in women” — and warns that “Women should not handle crushed or broken PROPECIA tablets when they are pregnant or may potentially be pregnant.”

One point of precision: the label carries no FDA boxed warning. The wording “depression, suicidal ideation and behavior” sits in the postmarketing part of Adverse Reactions, beside reports of sexual dysfunction. Read it, and take any questions to a licensed clinician.

Topical minoxidil, over the counter

Topical minoxidil needs no prescription and prints its approved use on the carton. The men’s 5% and women’s 5% products both give “to regrow hair on the top of the scalp”, the men’s adding “vertex only”; a women’s 2% solution gives “Use to regrow hair on the scalp”. On timing, the men’s 5% says “Results may occur at 2 months”, but “at least 4 months” for some men; the women’s 5% says results “may occur at 3 months”, with at least six months for some women.

These products are approved under their own New Drug Applications — the women’s 2% solution under NDA 019501 — not under a general over-the-counter monograph; that is our reading of FDA’s label filings. Our hair-loss clinic reviews set out which each program ships, and at what price.

Three medicines that turn up constantly on hair-loss menus are FDA-approved for something else: oral minoxidil for high blood pressure, dutasteride for an enlarged prostate, spironolactone for fluid and hormone conditions. None of their labels mentions hair loss.

FDA has a page for this. “Unapproved use of an approved drug is often called ‘off label’ use,” it writes, and such use can involve “a disease or medical condition, a dosage, a dosage form, or a route of administration not included in the approved labeling.” A licensed clinician may prescribe this way. Off-label is not unregulated: the drug went through FDA approval and carries a full FDA label that describes a different condition.

What each label says

• Oral minoxidil tablets. The generic label (updated November 18, 2025) says the tablets “are indicated only in the treatment of hypertension that is symptomatic or associated with target organ damage”. Its “BOXED WARNING” opens: “Minoxidil tablets contain the powerful antihypertensive agent, minoxidil, which may produce serious adverse effects.”
• Dutasteride. The AVODART label (revised 01/2020) says the drug is “indicated for the treatment of symptomatic benign prostatic hyperplasia (BPH) in men with an enlarged prostate”. Hair loss is not a listed use.
• Spironolactone. Aldactone (revised January 2008) and the generic (February 2015) list primary hyperaldosteronism, edematous conditions, essential hypertension, hypokalemia and severe heart failure. Both open with a boxed “WARNING” that spironolactone “has been shown to be a tumorigen in chronic toxicity studies in rats”.

One thing works in your favor: on our reading, none of these is a federally controlled substance. DEA’s schedules cover drugs with abuse or dependence potential, and none of the labels we pulled carries the schedule designation a controlled drug must display — so the federal telemedicine rules for controlled substances do not apply.

The questions for an off-label option are short: which drug, what is it approved for, and why this one for me? Ask the clinician who would write the prescription.

Some programs offer a topical finasteride, or one bottle blending several actives. Those are compounded preparations: a different regulatory category, lawful and long established, with a different set of rules.

Compounding is a licensed pharmacist or physician combining or altering ingredients for a patient. There are two lanes:

• 503A pharmacies. Drugs compounded by a licensed pharmacist or physician in a state-licensed pharmacy or federal facility, under section 503A of the Federal Food, Drug, and Cosmetic Act, are exempt from requirements that otherwise apply to drug manufacturing: new-drug approval, current good manufacturing practice and some labeling (FDA on compounding laws).
• 503B outsourcing facilities. FDA calls these “a category of compounders established in 2013 by the Drug Quality and Security Act”, which register with FDA and are “inspected by FDA according to a risk-based schedule” (FDA on 503B).

The rule covering both lanes: compounded drugs are not approved by FDA, which “does not verify the safety, effectiveness or quality of compounded drugs before they are marketed.” FDA also separates them from generics: a generic “is approved by FDA under 505(j) of the FD&C Act”, it says, “while a compounded drug is not approved by FDA”. So a compounded product is not a generic, and not an equivalent of the brand it resembles.

The April 2025 alert on compounded topical finasteride

On April 22, 2025 FDA posted an alert on “potential risks associated with compounded topical finasteride products”. Two statements are about approval status. FDA says “there is no FDA-approved topical formulation of finasteride.” These products, it adds, “do not have FDA-approved labeling.”

The alert is not a recall and not a ban: compounded topical finasteride is still prescribed and dispensed, and FDA’s recommendation is to “consult with health care providers and compounders regarding potential risks prior to initiation of treatment.” What the agency wants a buyer to know is that absorption happens — it says “Absorption of finasteride through the skin into the bloodstream is expected” — and that it has received reports of side effects of the kind listed on the oral label, including mood and sexual side effects, some of which people reported continuing after they stopped. It also notes a “greater potential risk for inadvertent exposure to others, specifically females, through transfer of applied product”; finasteride is contraindicated in pregnancy. The full list of reported events is in the alert, linked above, and it is worth reading before a first order.

A bottle combining several actives is a compounded preparation too, with the same status: no FDA approval, no agency-reviewed labeling, no review before marketing. Ask which pharmacy compounds it, and whether it is 503A or 503B; a page naming both has given you something checkable. Our guide to 503A and 503B pharmacies goes deeper, and the telehealth terms glossary defines the wording you meet at checkout.

Two more things show up in hair-loss carts: laser devices and supplements. Both are regulated, though not like a prescription drug.

“Cleared” and “approved” are different findings

Laser caps, combs and helmets are medical devices. One route to market is a 510(k), which FDA describes as a “premarketing submission” used to demonstrate that “the device to be marketed is as safe and effective, that is, substantially equivalent (SE), to a legally marketed device.” Premarket approval is the other route, “the most stringent type of device marketing application required by FDA”, needing evidence of “reasonable assurance that the device is safe and effective for its intended use.”

So a cleared device has been found substantially equivalent to one already legally on sale — not the same as FDA reviewing evidence that it works. A device cleared through 510(k) is accurately “FDA-cleared”; only a device that went through premarket approval is “FDA-approved”. If a page uses the second word, ask which route it took.

Supplements are not approved before they are sold

FDA is blunt here: “Vitamins, minerals, herbs, and other dietary supplements are NOT FDA-approved to treat or prevent disease.” Its dietary supplements page gives the reason: “Under DSHEA, FDA does not have the authority to approve dietary supplements before they are marketed.” That describes the process, not any one bottle — but “FDA-approved” is never the right phrase for a hair supplement.

Biotin is in most of them, and FDA keeps a safety communication about it: “Biotin, often found in dietary supplements, can significantly interfere with certain lab tests and cause incorrect test results which may go undetected.” Tell your clinician and the lab what you take before blood work.

All of this is public, which is the useful part. Five checks:

1. Read the product page’s own FDA wording. A program selling oral finasteride 1 mg or topical minoxidil can name the drug and say so plainly; one selling a compounded preparation should say it is compounded and not approved by FDA. A compounded product called a “generic”, or a device called approved, is worth a question.
2. Look the drug up in Drugs@FDA. Drugs@FDA is FDA’s database of approved drug products and their labeling. If a product is approved it is in there, with the indication in FDA’s words, not the seller’s.
3. Check the pharmacy. FDA runs BeSafeRx so you can “make safer, more informed decisions when purchasing prescription medicine from an online pharmacy”. NABP runs safe.pharmacy, an “accreditation program for online pharmacies” it began in 1999, and a state board directory that points you to the board licensing the pharmacy.
4. Check the clinician. The Federation of State Medical Boards runs DocInfo.org, which its consumer page says shows, per physician, “Disciplinary actions, License history, Medical school, Type of degree” and board specialty.
5. Confirm the state license. HHS’s telehealth guidance is that a health professional must “be licensed or legally permitted to practice in the state where the patient is located”. Ask which clinicians hold a license in your state.

Then the step no database does: take the shortlist to a licensed clinician who knows your history. This guide describes what FDA has and has not approved; it is not medical advice, and not a reason to start or stop a medicine.

To compare programs on price and on what they ship, our hair-loss clinic hub collects the reviews, including Hims, Hers and Ro.